Taurine-based Active Pharmaceutical Ingredient Ionic Liquids Modulate the Perifollicular Microenvironment for Androgenic Alopecia Treatment.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal research without human data
PubMed 42316299 · doi:10.1002/adhm.71363
What was done
Researchers synthesized a taurine-based active pharmaceutical ingredient ionic liquid (CTIL) via a one-step method designed to serve as both a transdermal delivery carrier and a reactive oxygen species (ROS) scavenger. They evaluated skin barrier penetration and follicle accumulation in vitro, and measured effects on perifollicular ROS, oxidative tissue damage, inflammatory infiltration, follicle miniaturization, and hair regrowth in an animal model of androgenic alopecia.
What was found
The abstract reports no numerical findings. Qualitatively, in vitro assays showed that CTIL penetrated the stratum corneum barrier and accumulated in deep hair follicle structures. In an animal model, CTIL scavenged perifollicular ROS, reduced oxidative damage and inflammation, inhibited hair follicle miniaturization, and promoted hair regrowth.
Why it matters
The study demonstrates a dual-function drug-delivery and antioxidant platform that addresses poor transdermal permeability of small molecules in treating androgenic alopecia.
Limits
The study is restricted to in vitro and animal models with no human subjects. The abstract does not disclose the animal species, sample size (n), quantitative effect sizes, comparative controls, or long-term safety profiles.
Cited by
- supports Deficiencies in taurine or taurine supplementation are linked with hair loss and hair growth.